Skeletal-related events (SREs) are common in patients with osteolytic lesions from multiple myeloma (MM), and result in substantial morbidity. We report herein a comprehensive, retrospective, multivariate analysis of prognostic factors for survival and first on-study SRE in MM patients using data from the phase III, randomized study comparing zoledronic acid with pamidronate in MM or breast cancer. Cox regression analyses were used to assess 22 variables for prognostic significance (defined as associations with Po0.05) in patients with bone metabolism marker assessments and complete baseline variable data. Of 510 evaluable MM patients, 282 had complete covariate information and were included in models. Reduced Cox multivariate models identified five significant prognostic factors for first SRE (weight, race, high N-terminal cross-linked telopeptide of type I collagen (NTX), high pain score, and need for narcotic analgesics) and seven for survival (age, SRE history, myeloma subtype, anemia, high lactate dehydrogenase, high NTX, and low albumin levels). High NTX was the only variable associated with elevated risks of both first SRE and death (Pp0.02 for each). These analyses identified prognostic factors for SREs and survival in patients with MM. Taken together with current staging systems, these factors could further facilitate decision making for optimal treatment of myeloma bone disease, although further prospective assessments are needed.
Introduction
Osteolytic bone lesions develop in nearly 90% of patients with multiple myeloma (MM), and are associated with substantial morbidity. 1 Patients with bone lesions experience substantial bone pain and are at risk for potentially debilitating skeletalrelated events (SREs) such as pathologic fractures, spinal cord compression, increased need for palliative radiotherapy or orthopedic surgery, and hypercalcemia of malignancy.
1 Survival for patients with MM is highly variable, and ranges from o6 months to 410 years. 2 Factors earlier identified as independent predictors of survival include severity of bone lesions, hemoglobin levels, serum calcium, serum creatinine, etc. 2 These factors have been used to develop staging systems for MM such as the Durie-Salmon staging system 3 and, more recently, the International Staging System (ISS). 2 The Durie-Salmon system used the type of paraprotein; levels of serum paraprotein, hemoglobin, creatinine, and calcium; and the number of bone lesions to define disease stage. The ISS is a simpler, three-stage classification that uses serum b 2 -microglobulin levels and albumin levels for staging. However, the ISS does not consider the extent of bone disease, which is the major clinical manifestation of this malignancy. 2 These staging systems are routinely used to predict survival and to guide treatment decisions in patients with MM. In addition to the factors considered in these established staging systems, recent evidence supports the prognostic value of cystatin-C (a sensitive indicator of renal impairment and cancer burden) and indicates a potential prognostic function for serum lactate dehydrogenase. 4 However, the risk factors for SREs and death have not been fully elucidated in the MM setting.
Osteolytic bone lesions in MM are characterized by perturbed skeletal homeostasis, resulting in elevated levels of bone resorption. These disturbances in normal bone metabolism may be detected by measuring biochemical markers of bone turnover such as the resorption marker N-terminal cross-linked telopeptide of type I collagen (NTX), the bone formation marker bone-specific alkaline phosphatase, and the ratio of the osteoclast regulators soluble receptor of nuclear factor k-B ligand (sRANKL) and osteoprotegerin (OPG). [5] [6] [7] Associations between pretreatment levels of NTX and disease progression during chemotherapy, 5 and between the sRANKL:OPG ratio and survival, 7 show the potential usage of bone turnover markers in MM. Studies in patients with bone metastases from solid tumors further show that elevated levels of bone turnover markers are associated with increased risk of SREs in the absence of antiresorptive therapy. 8 The negative impact of SREs is not limited to increased morbidity and treatment costs: some studies show that pathologic fractures in particular are associated with substantial increases in mortality among patients with MM or bone metastases from solid tumors. 9, 10 Therefore, the contribution of cancer-bone interactions to mortality and other clinical outcomes is complex.
Bisphosphonates inhibit osteolysis and are the current standard of care for treatment of hypercalcemia of malignancy and SREs in patients with bone lesions from MM. 11 Recent studies in patients with bone metastases from solid tumors (breast, prostate, lung, and other cancers) show that elevated levels of the bone resorption marker NTX are not only associated with increased risk of SREs and death, 12 but may also predict increased benefits from antiresorptive therapy. 13 As a result, there has been considerable interest in the use of bone turnover markers for assessing risks of SREs and death and for monitoring response to bisphosphonate therapy in patients with bone lesions from MM.
The phase III, multicenter trial comparing zoledronic acid (ZOL) with pamidronate (PAM) in patients with osteolytic lesions from MM or bone metastases from breast cancer provides an extensive data set of patients who were followed for 2 years with regard to SREs and survival, and who had measurements for several clinical and biochemical parameters of interest assessed at randomization and throughout the trial. In the present analysis, we have used this large database to evaluate the prognostic value of a range of potential risk factors for SREs and death in univariate and multivariate analyses.
Materials and methods

Patients
Patients with MM in the randomized, double-blinded, multicenter study to evaluate the safety and efficacy of ZOL versus PAM were included in this analysis. 14, 15 The main efficacy end point of the original trial compared the proportion of patients with on-study SREs (defined as pathologic fracture, palliative radiotherapy to bone, surgery to bone to prevent or treat an impending fracture, and spinal cord compression) for ZOL 4 mg versus PAM 90 mg. Concomitant anticancer treatment was determined by individual physicians based on clinical needs. Patients with impaired renal function (serum creatinine 43 mg/ 100 ml) or elevated serum calcium (X12 mg/100 ml) were excluded from the trial. Patients received intravenous infusion of ZOL (4 or 8 mg that was later reduced to 4 mg based on direction from the renal safety monitoring board), or PAM 90 mg every 3-4 weeks for up to 24 months.
The design, patient evaluation, and efficacy end points of this phase III, randomized, non-inferiority trial have been reported earlier. 14, 15 The trial prospectively recorded SRE-related data for each patient, including the occurrence and timing of each of the four defined SREs and hypercalcemia of malignancy. The primary end point of the trial was the proportion of patients with one or more SREs in each treatment arm. Secondary end points included overall survival and time to first SRE. As outcomes were similar between treatment arms, all patients with MM (n ¼ 510) were included in this analysis regardless of treatment. The multivariate analyses were limited to patients with complete baseline prognostic variables (n ¼ 282).
Statistical methods
Descriptive statistics were used to characterize the baseline variables. A panel of 22 variables was assessed for potential association separately for first SRE and death in univariate and multivariate Cox regression analyses. The results were expressed as relative risks with the associated 95% confidence intervals. Associations with Po0.05 were considered statistically significant. The variables assessed in baseline-evaluable patients were age (n ¼ 510), weight (n ¼ 493), race (n ¼ 510), gender (n ¼ 510), myeloma duration (n ¼ 509), brief pain inventory (BPI) composite pain score (n ¼ 451), use of narcotic analgesics (n ¼ 508), functional assessment of cancer therapy-general score (n ¼ 441), Eastern Cooperative Oncology Group performance status (n ¼ 509), SRE history (n ¼ 508), myeloma subtype (n ¼ 504), lymphocyte count (n ¼ 490), hemoglobin (n ¼ 498), serum glutamic-oxaloacetic transaminase (n ¼ 506), serum albumin (n ¼ 506), serum creatinine (n ¼ 506), serum calcium (n ¼ 506), lactate dehydrogenase (n ¼ 506), levels of the bone turnover markers NTX (n ¼ 318), bone-specific alkaline phosphatase (n ¼ 319), deoxypyridinoline (n ¼ 309), and pyridinoline (n ¼ 309). Bone marker assessments were available for North American patients only, and, therefore, limited the number of patients included in multivariate statistical models. All models were stratified by treatment group (ZOL 4 and 8/4 mg only). Age, weight, BPI score, functional assessment of cancer therapygeneral score, myeloma duration, and all bone marker levels were assessed as continuous variables because there is no established upper limit of normal (ULN) for these parameters in the MM patient population. MM subtypes were categorized based on the immunoglobulin (Ig) secreted as IgG, IgA, or light chain/non-secretory/IgM. All other covariates were treated as dichotomous variables, using the ULN as the cut point for numerical values. Reduced Cox multivariate models were generated by stepwise backward elimination of the least significant variables in the multivariate analyses until only significant covariates (Po0.05) remained.
Results
Baseline demographics
This phase III trial in patients with bone metastases from breast cancer or osteolytic lesions from MM enrolled 513 patients in the MM stratum.
14 Baseline data were available for 510 patients for at least 1 of the 22 variables of interest (Table 1) , and these were included in analyses. Median age of the patients was 62 years (range, 33-89 years). Approximately 60% of the patients were classified as having myeloma with secretory IgG. Consistent with advanced MM, the majority of patients (480%) had experienced at least 1 SRE before study entry. Complete baseline assessments for all variables were available for 282 of the 510 patients, and the baseline characteristics and rates of first on-study SREs and death were similar for this subset and for the 510 patients with any available baseline data for any of the variables ( Table 1 ). The univariate (all patients with available data for the respective variables) and multivariate models (n ¼ 282) were fit to these data.
Univariate and multivariate analyses of risk factors for first on-study SRE Potential risk factors for the first on-study SRE were evaluated using categoric and continuous variables as described above. In univariate analyses (Table 2 ), a total of 262 first-SRE events were assessed, and factors associated with a significantly increased risk of first SRE included lower weight, lower functional assessment of cancer therapy-general scores, higher BPI scores, race (white versus others), the need for narcotic analgesics, IgA subtype myeloma (versus IgG subtype), and higher levels of the bone turnover markers NTX, pyridinoline, and deoxypyridinoline. In the full multivariate model (Table 2 ), a total of 139 first-SRE events were assessed, and factors associated with significant increase in the risk of first on-study SRE were lower weight (8% increased risk of first SRE per 5-kg decrease in weight; P ¼ 0.007), higher BPI scores (16% increase in SRE risk per 1-unit increase in BPI score; P ¼ 0.002), and race (40% increase in SRE risk for white versus other races; P ¼ 0.034).
In the reduced multivariate model (Figure 1 ), each of the significant factors from the full multivariate analysis remained significantly associated with the risk of first SRE. Moreover, this reduced model identified two additional significant covariates: the need for narcotic analgesics and higher NTX levels. On the basis of this reduced model, risk of a first on-treatment SRE is increased by approximately 6% per 5-kg decrease in weight; by approximately 15% per unit increase in BPI score; and by 60% or more in white patients (versus other races), patients who needed narcotic analgesics (versus those who did not), or patients with elevated NTX (68% increase in risk per 100-unit increase).
Univariate and multivariate analyses of risk factors for survival
Univariate analyses (Table 3) of 182 deaths on-study revealed significant associations between risk of death and increased age, BPI pain scores, need for narcotic analgesics, Eastern Cooperative Oncology Group performance status, IgA myeloma subtype, history of earlier SREs, higher levels of bone turnover markers (NTX, deoxypyridinoline, and pyridinoline), serum glutamicoxaloacetic transaminase levels higher than the ULN, and low hemoglobin and albumin levels. In the full multivariate model (Table 3) of 94 deaths on-study, factors associated with significantly increased risk of death were age (3% increased risk of death per 1-year increase in age; P ¼ 0.008), earlier SRE (nearly 2.5-fold increase in risk of death versus patients without an earlier SRE; P ¼ 0.015), IgA/light chain/non-secretory/IgM myeloma subtype versus IgG (1.8-to 2.3-fold increased risk; Pp0.04 for each), hemoglobin o100 g/l (approximately 40% increased risk; P ¼ 0.031), and lactate dehydrogenase above the ULN (twofold increase in the risk of death; P ¼ 0.038). Values collected during the clinical trial were measured in conventional units and have been converted to SI units using the conversion factor 1 g/100 ml ¼ 10 g/l.
Risk of death and skeletal events in myeloma E Terpos et al All significant covariates identified in the full multivariate model were retained in the reduced model (Figure 2) , with the exception of light chain/non-secretory/IgM myeloma subtype. Instead, high NTX levels (relative risk ¼ 1.60; P ¼ 0.017) and low albumin levels (relative risk ¼ 1.68; P ¼ 0.025) entered this model as significant prognostic factors for death. Interestingly, the greatest increase in the risk of death (2.7-fold; P ¼ 0.004) was observed in patients with a history of SREs before study entry.
Discussion
Current staging systems for MM facilitate decision making for optimal anticancer therapies. However, the current ISS does not consider the presence and extent of bone lesions relevant to the decision-making process. Patients with osteolytic bone lesions from MM are at risk for SREs, which might negatively affect survival in addition to substantially increasing morbidity. The Table 2 Cox regression analysis of associations between baseline variables and first skeletal-related event Risk of death and skeletal events in myeloma E Terpos et al analyses described herein identify risk factors for SREs and death among MM patients with osteolytic lesions who receive intravenous bisphosphonate therapy. We show that patient characteristics associated with advanced disease, such as decreased weight and pain needing narcotic analgesics, are significant prognostic factors for the development of SREs. Risk of death and skeletal events in myeloma E Terpos et al Furthermore, we identified several additional factors associated with decreased survival: these were derived from both diseaserelated characteristics (for example myeloma subtype, anemia, and history of an earlier SRE) and patient characteristics (for example age) at baseline. In the current analysis, NTX was analyzed as a continuous variable because it does not have an established ULN in the MM patient population. Nonetheless, NTX was found to be an important prognostic indicator and a strong component in each of the reduced models for both first SRE and death. As NTX levels reflect ongoing rates of osteolysis, patients with elevated NTX levels might have more numerous and/or more aggressive osteolytic lesions. 6 Consistent with our present findings, elevated NTX levels have been associated with increased risks of SREs (twofold increase) and death (fourfold or greater increase) among patients with bone metastases from solid tumors (n ¼ 1056). 12 Restoration of skeletal homeostasis may reduce the risk of SREs and improve overall clinical outcomes for patients with malignant bone disease. Decreased risk of SREs with bisphosphonate therapy is accompanied by decreases in NTX levels in patients with bone lesions from MM. 14, 16 Moreover, normalization of elevated NTX levels within 3 months of ZOL treatment was associated with reduced risks of SREs and death in patients with bone metastases from breast cancer and other solid tumors. 17, 18 Monthly ZOL was also found to improve survival in patients with bone metastases from lung cancer and elevated levels of NTX at baseline. 13 A recent large randomized study shows that the addition of ZOL (4 mg every 6 months) to adjuvant hormonal therapies (which are typically associated with elevations in bone resorption markers such as NTX) delayed disease progression and improved disease-free survival in women with early stage breast cancer. 19 Therefore, it is postulated that, in addition to the obvious benefits to skeletal health, antiresorptive therapy might also have a positive impact on survival for patients with MM. However, further research is needed to elucidate the effects of antiresorptive therapy in general and NTX normalization, in particular, on clinical outcomes in patients with MM. The results from ongoing clinical trials, such as the Myeloma IX trial (ISRCTN68454111; sponsored by the Medical Research Council UK), are expected to further advance our understanding of primary antimyeloma therapy and antiresorptive treatment in patients with MM.
The current analyses have certain limitations that must be taken into consideration. First, these analyses were restricted to MM patients with confirmed osteolytic lesions. In this specific subset of patients, some of the assessed baseline characteristics could be correlated. For example, levels of the bone resorption marker NTX could be correlated with levels of the other bone markers assessed in this study, and these factors would then compete for statistical significance in multivariate models. For that reason, both the univariate and multivariate models were included in this report, so that the relationships between variables and the clinical outcomes could be viewed both independently (univariate models) and in the context of all the assessed covariates (multivariate models) or only those found to have robust statistical correlations with the clinical outcomes (reduced multivariate models). Second, these are retrospective analyses of data from a trial conducted before the introduction of novel antimyeloma therapies (that is immunomodulatory drugs and bortezomib-based regimens). Third, the phase III trial of ZOL versus PAM in MM was conducted before introduction of the current ISS. As a result, inclusion criteria for patients in this trial were based on the older Durie-Salmon staging system for MM, and serum b 2 -microglobulin levels were not measured at study entry. Therefore, further studies in patients staged using the ISS and receiving targeted therapies are required to validate these findings. Moreover, in earlier analyses of this phase III trial database, patients were divided into three categories based on NTX levels, which revealed inconsistent correlations in MM patients. 12 However, patients with MM experience both generalized bone loss and the development of primary bone lesions in areas of bone heavily colonized by myeloma cells, and the use of specific NTX cutoff values based on normal levels in other settings might not be appropriate. Nonetheless, our results provide a rationale for prospective monitoring of NTX levels during treatment of myeloma bone disease and provide support for additional prognostic variables in this setting, as reflected in the reduced multivariate models.
This analysis is the first to identify significant risk factors for SREs in patients with MM. These risk factors can help identify patients who are at high risk for SREs or death, who may be candidates for more aggressive treatment or preventive followup. Moreover, assessment of these risk factors may also facilitate decisions regarding the need to change therapy or initiate supportive care. Despite this retrospective analysis being conducted in patients staged using the Durie-Salmon system, prognostic factors identified in the survival analyses were consistent with the only factor routinely evaluated in these patients (serum albumin) that is also included in the current ISS. 2 In addition, our survival analyses identified additional important prognostic factors, including baseline levels of the bone turnover marker NTX. In the past, changes in bone marker levels over time have shown promise for predicting SREs in small studies in patients with bone lesions from MM. 20 A recent analysis of prognostic factors in a group of 100 patients with newly diagnosed, symptomatic MM identified carboxy-terminal telopeptide of type I collagen (ICTP) as an important prognostic factor for survival. 21 In this study, baseline ICTP levels identified patients with poor prognosis within each of the three stages described using the ISS (Pp0.027 for each), and use of a combined ICTP-ISS scoring system significantly improved prediction of 5-year survival compared with ISS alone (Po0.001). 21 Ongoing analyses using larger trial databases are now investigating the usage of changes in bone marker levels to monitor patients during therapy, and the results are eagerly awaited.
The current analyses also identified a history of SREs before initiation of bisphosphonate therapy as a significant prognostic factor for reduced survival. Indeed, patients who had a history of SREs had 42.5-fold increase in the risk of death compared with patients who did not have an SRE before initiating bisphosphonate treatment. This result was consistent with a recent retrospective study showing an increased risk of death among MM patients who develop SREs during the course of their disease. 22 This is also consistent with earlier findings in patients with bone metastases from breast cancer, prostate cancer, lung cancer, and other solid tumors, 10 and with the observation that pathologic fractures increased the risk of death in patients with MM. 9 These results, therefore, underscore the importance of early treatment with bisphosphonates for patients with bone lesions from MM because treatment to prevent the first SRE may also reduce the risk of death compared with withholding treatment until after an SRE develops.
Overall, our present findings identify several risk factors for SREs and death that have the potential to aid clinical decision making in the optimal management of myeloma bone disease, and highlight the need for therapeutic approaches that maintain skeletal integrity and prevent the onset of SREs in the advanced MM setting. Our results also indicate that, in addition to assessing the standard clinical risk factors that we have identified, monitoring bone turnover levels using NTX might provide valuable insights into the risk of negative clinical outcomes. Data from ongoing prospective trials are expected to further reinforce the function of such bone markers in disease monitoring and prognosis.
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